Trials / Conditions / Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura

27 registered clinical trials studyying Thrombotic Thrombocytopenic Purpura — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Longitudinal Cohort of Thrombosis and Hemostasis Diseases NCT06727669	Peking University People's Hospital	—
Completed	Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune NCT05468320	Sanofi	Phase 3
Not Yet Recruiting	Aspirin for Prophylaxis of TTP NCT05568147	The First Affiliated Hospital of Soochow University	Phase 2 / Phase 3
Unknown	A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian E NCT05785468	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	—
Unknown	Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia NCT04588194	David Gomez Almaguer	Phase 2
Unknown	The ConNeCT Study: Neurological Complications of TTP NCT04981028	Liverpool University Hospitals NHS Foundation Trust	—
Completed	A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) NCT04074187	Sanofi	Phase 2 / Phase 3
Unknown	TTP and aHUS in Complicated Pregnancies NCT03605511	University College, London	—
Unknown	Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care NCT03237819	Assistance Publique - Hôpitaux de Paris	Phase 3
Completed	Observational Study of the Use of octaplasLG®. NCT03369314	Octapharma	—
Terminated	Octaplas Adult TTP Trial NCT01938404	Octapharma	—
Unknown	A Prospective Study on the Long-Term Vascular Burden in Thrombotic Thrombocytopenic Purpura Patients NCT03187652	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	—
Unknown	.German TTP-Registry (Thrombotic Thrombocytopenic Purpura) NCT05389007	Johannes Gutenberg University Mainz	—
Withdrawn	The Role of Microparticles as a Biomarker NCT02626663	University of Rochester	—
Completed	Early Predictive Factors of Cardiac and Cerebral Involvement in TMA NCT02134171	Assistance Publique - Hôpitaux de Paris	N/A
Completed	At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurolo NCT01931644	Sanguine Biosciences	—
Completed	Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura NCT01554514	Washington University School of Medicine	Phase 2
Completed	Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura NCT00907751	Assistance Publique - Hôpitaux de Paris	Phase 2
Terminated	Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura NCT00799773	Carelon Research	Phase 3
Terminated	Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy NCT00726544	Archemix Corp.	Phase 2
Terminated	Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Pur NCT00953771	Icahn School of Medicine at Mount Sinai	Phase 2
Unknown	Rituximab in Patients With Relapsed or Refractory TTP-HUS NCT00531089	Hamilton Health Sciences Corporation	Phase 2
Completed	Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpu NCT00713193	Ohio State University	Phase 3
Terminated	International Registry and Biorepository for TMA(Thrombotic Microangiopathy) NCT00593229	Northwell Health	—
Completed	ADAMTS13 in Thrombotic Thrombocytopenic Purpura NCT00426686	Assistance Publique - Hôpitaux de Paris	—
Recruiting	Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome NCT01257269	Insel Gruppe AG, University Hospital Bern	—
Withdrawn	Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpu NCT00251277	Weill Medical College of Cornell University	Phase 1 / Phase 2